Blood markers for cancer
BMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l5774 (Published 14 October 2019) Cite this as: BMJ 2019;367:l5774- Jessica Watson, NIHR doctoral research fellow1,
- Luke Mounce, research fellow2,
- Sarah ER Bailey, research fellow2,
- Sharon L Cooper, patient contributor2,
- Willie Hamilton, professor of primary care diagnostics2
- 1Centre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK
- 2University of Exeter, Exeter, UK
- Correspondence to W Hamilton W.Hamilton{at}exeter.ac.uk
What you need to know
“Triage” blood tests in primary care, such as haemoglobin, platelets, serum calcium level, liver function tests, and inflammatory markers such as C reactive protein and erythrocyte sedimentation rate may provide “clues” to cancer in patients with non-specific symptoms
Triage tests do not have the performance characteristics of rule-out tests
Evidence supports the use of only a small number of specific cancer markers, such as CA125 and PSA, in primary care
A 61 year old man with a one month history of back pain visits his general practitioner (GP). He has hypertension, has never smoked, and reports fatigue for several months. The pain is keeping him awake at night. He has not lost weight. Clinical examination is normal. The differential diagnosis for this patient is wide, including potential malignant causes such as pancreatic, myeloma, and prostate cancer or metastatic disease.
Cancer can be difficult to identify, as many of the common symptoms are non-specific and low risk, and even the most well known “alarm” symptoms have relatively low positive predictive values (PPVs) for underlying malignancy.1 For example, weight loss has a PPV for underlying malignancy of only 0-3.3%,2 while rectal bleeding has a PPV of 2.2-15.8%.3 Cancer markers used in hospital settings, when applied to low risk primary care patients, have low positive predictive values and high false positive rates.4 Identifying patients whose non-specific symptoms may be caused by cancer, rather than benign disease, is therefore a challenge for primary care physicians.
While formal diagnosis usually happens in secondary care, the first suspicion of cancer generally occurs in primary care. Patients whose symptoms represent an approximate risk of cancer of ≥3% are recommended by the National Institute for Health and Care Excellence (NICE) for urgent investigation, often by referral.5 Those with estimated risk <3% may receive …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.